GlassScriptPhysician profile
Rajesh Kumar Jari
NPI 1427194356
$26,468.11
in general payments reported to CMS, 2019-2025
46 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,463 · 2020: $1,282 · 2021: $1,721 · 2022: $1,664 · 2023: $8,268 · 2024: $8,937 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $12K · Food and Beverage: $5,165 · Travel and Lodging: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $12,154.40 |
| Food and Beverage | $5,165.41 |
| Travel and Lodging | $1,018.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $12,169.21 | 2023-2024 | Rs4i Plus Sequential Stimulator, Rs-Lbg, Rs-Fbg |
| Abbott Laboratories | $4,182.13 | 2019-2025 | Eterna, Proclaim |
| Nevro Corp. | $1,633.29 | 2019-2024 | Senza |
| Spinal Simplicity, LLC | $1,368.55 | 2023-2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $1,356.58 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Kyphon Express II Kyphopak Tray |
| Vertos Medical, INC. | $611.60 | 2022-2024 | Mild Device Kit |
| Abbvie INC. | $513.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.20 | 2019-2025 | Relistor |
| Pfizer INC. | $463.05 | 2019-2025 | |
| Protega Pharmaceutials INC | $444.86 | 2023-2024 | Roxybond |
| Saluda Medical Americas, INC. | $387.99 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $373.90 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Nuvasive, INC. | $350.78 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $280.81 | 2019-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $277.74 | 2023-2025 | Qutenza |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Jari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.